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Abstract: Chronic myeloid leukemia (CML) is the consequence of a single balanced translocation 
that produces the BCR-ABL fusion oncogene which is detectable in over 90% of patients at pre-
sentation. The BCR-ABL inhibitor imatinib mesylate (IM) has improved survival in all phases of 
CML and is the standard of care for newly diagnosed patients in chronic phase. Despite the very 
signiﬁ  cant therapeutic beneﬁ  ts of IM, a small minority of patients with early stage disease do not 
beneﬁ  t optimally while IM therapy in patients with advanced disease is of modest beneﬁ  t in many. 
Diverse mechanisms may be responsible for IM failures, with point mutations within the Bcr-Abl 
kinase domain being amongst the most common resistance mechanisms described in patients with 
advanced CML. The development of novel agents designed to overcome IM resistance, while 
still primarily targeted on BCR-ABL, led to the creation of the high afﬁ  nity aminopyrimidine 
inhibitor, nilotinib. Nilotinib is much more potent as a BCR-ABL inhibitor than IM and inhibits 
both wild type and IM-resistant BCR-ABL with signiﬁ  cant clinical activity across the entire 
spectrum of BCR-ABL mutants with the exception of T315I. The selection of a second generation 
tyrosine kinase inhibitor to rescue patients with imatinib failure will be based on several factors 
including age, co-morbid medical problems and ABL kinase mutational proﬁ  le. It should be 
noted that while the use of targeted BCR-ABL kinase inhibitors in CML represents a paradigm 
shift in CML management these agents are not likely to have activity against the quiescent CML 
stem cell pool. The purpose of this review is to summarize the pre-clinical and clinical data on 
nilotinib in patients with CML who have failed prior therapy with IM or dasatinib.
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Introduction
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized 
by the presence of the Philadelphia chromosome (Ph), which is the result of a balanced 
reciprocal translocation involving the long arms of chromosomes 9 and 22. The fusion 
gene that emerges (BCR-ABL) encodes a constitutively active protein tyrosine kinase 
that is primarily responsible for the leukemic phenotype.1,2 The disease typically affects 
patients with a median age of 66 years and accounts for 7% to 15% of newly diagnosed 
leukemia in adults. The incidence of CML is approximately 1 to 1.5 cases per 100,000 
population in the United States.3 According to the National Cancer Institute SEER 
(Surveillance and Epidemiology End Results) database, close to 4830 new cases will be 
diagnosed in the US in 2008 and of these, 450 patients will succumb to the disease. The 
natural history of CML begins with a chronic indolent phase (CML-CP) followed by an 
accelerated phase (CML-AP) and ﬁ  nally a blastic phase (BP) with transition being usually 
to either acute myeloid or acute lymphoblastic leukemia (AML, ALL). In the early days of 
CML management, treatment relied heavily on agents like hydroxyurea and busulfan with 
rapid progression to blastic phase disease and early death. Outcomes for CML patients Drug Design, Development and Therapy 2009:3 90
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improved somewhat with the arrival of cytarabine (Ara-C) and 
interferon (IFN); however, the prospect for long-term disease 
free survival was limited given the lack of efﬁ  cacy of available 
agents and the treatment related mortality (TRM) associated 
with allogeneic stem cell transplantation. The prognosis of 
patients with CML improved dramatically in the late 1990s 
following the introduction of imatinib mesylate (IM, Gleevec®, 
Glivec®; Novartis Pharmaceuticals), a ﬁ  rst in class novel and 
selective inhibitor of Bcr-Abl. In newly diagnosed patients with 
CML, IM is now associated with complete response rates of 
87%, progression rates to advanced disease (accelerated and 
blastic phase) of 7% and an estimated 5-year survival rate of 
89%, over 95% if conﬁ  ned to CML-related causes of death.4–6 
The development of IM represents one of the most signiﬁ  cant 
advances thus far achieved in anti-cancer therapy. While the 
introduction of IM has revolutionized the management of 
CML, there is a small minority of patients who will display 
primary or secondary resistance to treatment which has led to 
the development of a new era of second generation tyrosine 
kinase inhibitors of which nilotinib (Tasigna®, N-[3-[3-(1H-
imadazolyl)propoxy] phenyl]-4-methyl-3-[[4-(3-pyridinyl)-
2-pyrimidinyl]amino]benzamide; Novartis Pharmaceuticals) 
is highly effective, based on its balance of potent activity and 
excellent tolerance proﬁ  le. The selection of a second genera-
tion generation tyrosine kinase inhibitor to rescue patients with 
imatinib failure will be based on several factors including 
age, co-morbid medical problems and ABL kinase muta-
tional proﬁ  le. It should be noted that while the use of targeted 
BCR-ABL kinase inhibitors in CML represents a paradigm 
shift in CML management these agents are not likely to have 
activity against the quiescent CML stem cell pool which lead 
to disease progression or relapse in some patients.
Rationale for second-generation 
tyrosine kinase inhibitors
The pivotal IRIS trial (IM Compared with Interferon and Low 
Dose Cytarabine for Newly Diagnosed Chronic Phase Chronic 
Myeloid Leukemia), designed to compare prospectively the 
administration of IM daily to the combination of interferon-
alfa and cytarabine, recruited 1106 CML-CP patients across 
16 countries and was published in the New England Journal 
of Medicine in 2003.5 With a median follow up of 19 months, 
96% of patients achieved a complete hematological response 
(CHR) on the IM arm, 87% a major cytogenetic response 
(MCyR) and 76% of patients achieved a complete cytogenetic 
response (CCyR). With 6 years of follow up,6 CHR and CCyR 
rates were 97% and 83% respectively. An estimated 88% of 
patients remained alive and 93% of patients had not progressed 
from chronic phase disease. Despite these impressive data, 
disease progression may occur at an annual rate of 4% in the 
ﬁ  rst three years of therapy in CP patients7 and in patients with 
more advanced disease, response rates to IM are poor. The most 
likely explanation of apparent IM “failure” in most patients is 
of poor compliance with therapy. An unwelcome consequence 
of long-term therapy with an agent such as IM which is asso-
ciated with minimal adverse events is a decrement in patient 
compliance. A new challenge facing clinicians treating CML is 
the management of IM resistance (primary or secondary) and/
or intolerance. Primary IM resistance is deﬁ  ned by failure to 
reach speciﬁ  c hematologic and cytogenetic milestones within 
the ﬁ  rst 18 months of therapy whilst secondary resistance refers 
to loss of an initial objective response (Table 1).
IM intolerance
IM therapy is well tolerated in the majority of patients; 
however, a small group will be intolerant of therapy. Most 
reactions are of mild-to-moderate grade, but from available 
data the drug is discontinued for drug-related adverse 
reactions in 2.4% of newly diagnosed patients, in 4% of 
patients in chronic phase after failure of interferon-alpha 
therapy, in 4% of patients with AP and in 5% with BP. The 
most frequently reported drug-related adverse reactions are 
edema, nausea and vomiting, muscle cramps, musculoskeletal 
pain, diarrhea and rash. The frequency of severe superﬁ  cial 
edema is approximately 1.5% to 6%. These reactions appear 
to be dose related and are more common in older patients 
and in those with blast crisis and accelerated phase disease. 
Severe elevation of transaminases or bilirubin occurs in 
approximately 5% of IM-treated CML patients. Treatment 
was discontinued permanently because of liver laboratory 
abnormalities in less than 1.0% of these. With respect to 
hematologic toxicity, neutropenia and thrombocytopenia are 
consistent ﬁ  ndings. The occurrence of cytopenias in CML 
patients is also dependent on the stage of the disease. The 
median duration of the neutropenic and thrombocytopenic 
episodes varies from 2 to 3 weeks, and from 2 to 4 weeks, 
respectively.8 In general, adverse reactions can usually be 
managed with either a reduction of the dose or an interrup-
tion of treatment along with appropriate supportive measures 
(eg, growth factor support, diuretics, anti-emetics). In rare 
cases, however, permanent cessation of therapy is the only 
solution to manage the intolerant patient.
IM resistance
Many point mutations within the Abl-kinase protein 
have been reported – some appear, in some patients, to Drug Design, Development and Therapy 2009:3 91
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be mediators of IM resistance.9 IM binding to Bcr-Abl 
produces a closed inactive conformation; however, p-loop 
point mutations can change the crystal structure of Bcr-Abl 
producing an open conﬁ  guration such that IM binding is 
not possible.10,11 The T315I mutation consists of a single 
threonine substitution for an isoleucine residue at position 
315 of the Abl-kinase domain and gives rise to a highly 
resistant kinase present in 50% to 90% of relapsed CML 
patients.12–15 Other mutations target the activation loop and 
the catalytic domain of the molecule. It is very important 
to note that there is no current role for “screening” for 
BCR-ABL mutations in patients in ongoing response to IM. 
Ampliﬁ  cation of BCR-ABL may account for resistance to 
IM in a small percentage of cases and these patients may or 
may not respond to increased doses of the drug.9,16 Activa-
tion of the SFKs (Src family of kinases) and over-expression 
of Lyn kinase was postulated to potentially have a role in 
IM resistance.17 However as the clinical data have shown 
no clinical advantage to agents with both Bcr-Abl and 
Src inhibitory activity, eg, dasatinib, over the safer, more 
targeted nilotinib, which has no Src inhibitory activity, it 
seems increasingly unlikely that Src has any signiﬁ  cant role 
in clinical IM resistance. The presence of p-glycoprotein 
efﬂ  ux pumps through MDR-1 gene expression18 and plasma 
binding of α-1 acid glycoprotein19 with IM both prevent the 
drug reaching its target protein and may be responsible for 
treatment failure in some cases.
Given the new unmet needs in CML that emerged 
following IRIS, investigators began to explore the 
development of new compounds to overcome IM resistance 
(Figure 1).
Based on crystallographic studies, it was suggested that 
the potency and selectivity of IM could be improved by incor-
porating alternative binding groups to the N-methylpiperazine 
moiety of the compound. This led to the development 
of nilotinib, a high afﬁ  nity aminopyrimidine-based ATP 
competitive inhibitor (Figure 2).
Summary of pre-clinical 
development
The recommended dose for nilotinib in IM resistant/intolerant 
all phase CML is 400 mg twice daily by mouth.20 Like IM, 
nilotinib binds to the inactive conformation of the Abl-
tyrosine kinase, causing P-loop folding over the ATP binding 
site and activation loop blockade of the substrate binding site. 
These events disrupt ATP/substrate binding and inhibit the 
catalytic activity of the enzyme.21 The structural similarities 
of both IM and nilotinib result in a similar proﬁ  le of protein 
kinase targets. Dasatinib, which was designed originally as a 
potential immunosuppressive agent, ie, a Src-kinase inhibitor, 
has a very different structure and many more off-target kinase 
targets compared to IM and nilotinib, which is presumably 
responsible for the latter agents’ relatively toxic clinical 
prof ile (Table 2).
Table 1 Management of CML – Recommendations from the European LeukemiaNet (ELN): Proposed criteria for failure, suboptimal 
response, and warnings for previously untreated patients with early chronic phase CML who are treated with IM 400 mg daily
Time Failure “Suboptimal” response “Warnings”
Diagnosis N/A N/A High risk, del9q+,   ACAs in Ph+ cells
3 months after diagnosis No HR (stable disease or disease 
progression)
Less than CHR N/A
6 months after diagnosis Less than CHR, no CgR (Ph+  95%) Less than PCgR (Ph+  35%) N/A
12 months after diagnosis Less than PCgR (Ph+  35%) Less than CCgR Less than MMolR
18 months after diagnosis Less than CCgR Less than MMolR N/A
Any time Loss of CHR* Loss of CCgR† 
Mutation‡
ACA in Ph+ cells§ 
Loss of MMolR§ 
Mutation#
Any rise in transcript level. Other 
chromosomal abnormalities in Ph– 
cells
*To be conﬁ  rmed on two occasions unless associated with progression to accelerated phase/blast crisis.
†To be conﬁ  rmed on two occasions unless associated with CHR loss or progression to accelerated phase/blast crisis.
‡High level of insensitivity to IM.
§To be conﬁ  rmed on two occasions unless associated with CHR or CCgR loss.
#Low level of insensitivity to IM.
Deﬁ  nitions of failure, “suboptimal” response, and “warnings”
• ‘Failure’ indicates that continuing IM treatment at the current dose is no longer appropriate for the patient.
• ‘Suboptimal response’ indicates the patient may gain beneﬁ  t from continuing IM therapy but long-term outcomes may not be favorable.
• ‘Warnings’ are indications that standard-dose IM treatment may not be the best option for a particular patient, and careful monitoring is required.
Abbreviations: IM, imatinib mesylate; N/A, not applicable;   ACA, additional chromosomal abnormalities; HR, hematologic response; CCgR, complete cytogenetic response; 
PCgR, partial CgR; CHR, complete hematological response; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; MMoIR, major molecular remission.Drug Design, Development and Therapy 2009:3 92
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In IM-sensitive CML cell lines, nilotinib was 10- to 60-fold 
more potent an inhibitor than IM.22–25 The inhibitory activity 
of nilotinib is also several fold higher (3- to 7-fold) than that 
of IM in IM-resistant CML cell lines; however, no activity 
was seen in cell lines harboring the T315I mutation.24,25 
Preclinical data indicate that nilotinib effectively inhibits 
wild type BCR-ABL. At IC50 concentrations of over 150 nM, 
nilotinib was inactive against T315I (Figure 3).
Other protein kinase targets of nilotinib include 
TEL-PDGFR β, FIP1L1-PDGFR α and D816V mutated 
KIT.26–30 Nilotinib, therefore, may have a place in the treat-
ment of idiopathic hypereosinophilic syndrome (HES), 
chronic myelomonocytic leukemia (CMML) and systemic 
mastocytosis (SM). Kinase domain mutations seem to be 
less frequent with nilotinib treatment and may respond to 
higher doses of the drug when they do occur.14 Murine models 
injected with IM-resistant Bcr-Abl cell lines survived longer 
with nilotinib treatment compared to controls.24,25 Other pre-
clinical studies suggest an additive effect when nilotinib is 
combined with IM.23,31 Pharmacokinetic data are available 
from a phase 1 dose escalation study published by Kantarjian 
and Giles et al in 2006.32 Nilotinib was administered orally 
at doses of 50 to 1200 mg once daily and at doses of 400 mg 
or 600 mg twice daily. All trough serum concentrations 
exceeded the IC50 values for cellular phosphorylation of 
BCR-ABL including 32 of 33 BCR-ABL mutants. Peak 
serum concentrations and area under the curve (AUC) val-
ues increased with once daily doses of 50 to 400 mg but at 
higher doses these values began to plateau, likely reﬂ  ecting 
saturation of gastrointestinal absorption. At the recommended 
400 mg twice daily dosing mean peak and trough serum drug 
concentrations were respectively 3.6 μmol/L and 1.7 μmol/L 
at 3 hours. The apparent elimination half-life of nilotinib was 
close to 17 hours, more than 90% of an administered dose 
is eliminated in the feces within 7 days and 70% of the dose 
is accounted for by the parent drug.20 Co-administration of 
nilotinib with ketoconazole in healthy volunteers resulted 
in a 3-fold increased systemic exposure to nilotinib, indi-
cating that nilotinib metabolism is influenced by cyto-
chrome P450 (CYP) 3A4 inhibition.32 In the same analysis, 
co-administration of nilotinib with midazolam resulted in a 
30% increase in midazolam exposure, implying that nilotinib 
Figure 1 Targeting the CML signaling cascade.42
Abbrevations: ABL, Abelson tyrosine kinase;  Akt, Protein kinase B; BCR, breakpoint cluster region; CRKL, V-crk sarcoma virus CT10 oncogene homolog (avian)-like; FAK, focal 
adhesion kinase; FTI, farnesyl transferase inhibitor; Grb-2, growth factor receptor-bound protein 2; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; P, phosphate 
group; PI3K, phosphatidylinositol-3-kinase; SFK, Src family kinases; SHC, Src homology 2 domain-containing; SRC, homolog of Rous sarcoma virus; Stat, signal transducer and 
activator of transcription.Drug Design, Development and Therapy 2009:3 93
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may be a weak inhibitor of CYP3A4. Therefore, concomitant 
use of both CYP3A4 inhibitors (eg, azole antifungals, clar-
ithromycin, atazanavir, ritonavir) and CYP3A4 inducers 
(eg, dexamethasone, phenytoin, carbamazapine) should be 
avoided. Based on embryo-fetal developmental studies in 
pregnant rats and rabbits, nilotinib is not considered to be 
teratogenic; however, there are no well controlled studies with 
nilotinib in pregnant women taking the drug. A pharmaco-
genetic analysis of 97 patients evaluated polymorphisms of 
UGT1A1 and the potential for hepatic impairment to occur 
(hyperbilirubinemia) in this group. The (TA)7/(TA)7 geno-
type was associated with a statistically signiﬁ  cant increase 
in the risk of hyperbilirubinemia relative to the (TA)6/(TA)6 
and (TA)6/(TA)7 genotypes.20
Summary of clinical development
The therapeutic efﬁ  cacy of nilotinib has been extensively 
evaluated in CML. The phase I component of the study consisted 
of a dose escalation study assessing the safety and tolerability of 
nilotinib in IM-resistant CML and Ph+ ALL, nilotinib eff icacy 
was assessed a secondary endpoint. The larger phase II trial 
recruited across numerous international leukemia centers of 
excellence. The protocol included 6 arms; 3 of those arms 
involved patients with IM failure in chronic phase, accelerated 
phase and blastic phase CML,33–35 2 arms considered all phase 
CML patients with prior IM and dasatinib failure, and the 
remaining arm included patients with Ph+ ALL and rarer dis-
orders such as the hyper-eosinophilic syndrome and systemic 
mastocytosis. To date, the results of the phase I study of both 
the phase II CP and AP CML trials have been published in 
mature form while initial data on the other studies are available. 
All of the trials included patients who had previously received 
IM therapy but were either unable to tolerate the drug or had 
either primary or secondary resistant disease. Throughout the 
conducted studies, deﬁ  nitions of remission and response are 
based on those put forward by the European Leukemia Network 
for CML (Table 3).
Safety and tolerability
The ﬁ  rst study in man of nilotinib was a multicenter, dose 
escalation study of orally administered drug on a continuous 
daily dosing schedule in adults with IM-resistant/intolerant all 
phase Ph+ CML and Ph+ ALL.32 The primary objectives of the 
trial were to determine the safety and tolerability of nilotinib 
and to characterize its biologic and pharmacokinetic proﬁ  les. 
Hematologic and cytogenetic responses were evaluated as 
IM
Auxiliary 
binding
pocket
Hydrogen bonds form to 
Glu286, Phe317, Thr31 & 
Asp381
Hydrogen
bonds to Ile360 
& His361 
NILOTINIB
Only maintains 4 hydrogen-bonds
Lipophilic interactions allow 
greater flexibility of protein 
surface, so nilotinib is less 
susceptible to point mutations 
Figure 2 Interaction of imatinib and nilotinib with BCR-ABL. The reduced requirement for hydrogen bonding with nilotinib compared to imatinib, allows for a tighter steric 
f it into the ATP binding pocket.Drug Design, Development and Therapy 2009:3 94
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Table 2 Targets of the ﬁ  rst- and second-generation tyrosine kinase inhibitors
Imatinib Nilotinib Dasatinib
ABL ABL ABL DDR1 MYT1
ARG ARG ARG DDR2 NLK
BCR-ABL BCR-ABL BCR-ABL ACK PTK6/Brk
KIT KIT KIT ACTR2B QIK
PDGFR PDGFR PDGFR ACVR2 QSK
DDR1 DDR1 SRC BRAF RAF1
NQO2 NQO2 YES EGFR/ERBB1 RET
FYN EPHA2 RIPK2
LYN EPHA3 SLK
HCK EPHA4 STK36/ULK
LCK EPHA5 SYK
FGR FAK TA03
BLK GAK TESK2
FRK GCK TYK2
CSK HH498/TNNI3K ZAK
BTK ILK
TEC LIMK1
BMX LIMK2
TXK
Notes:   The structural similarities of both imatinib and nilotinib result in a similar very limited proﬁ  le of protein kinase targets. Dasatinib, developed originally as a Src-kinase 
inhibitor, has a much broader range of non Bcr-Abl targets.
secondary endpoints. The trial recruited 119 patients (106 with 
Ph+ CML and 13 with Ph+ ALL) who were assigned to get 
either a 50 to 1200 mg (n = 69) dose once daily or a 400 mg or 
600 mg dose twice daily (n = 40). The protocol was amended 
to allow for dose escalation in patients with an inadequate 
initial response to therapy in the absence of signiﬁ  cant side 
effects. The median duration of therapy ranged from 4.9 to 
5.1 months among patients with CP or AP disease, and was 
shorter in patients with myeloid (2.9 months) versus lymphoid 
(1.4 months) BP. The most common adverse events reported 
were mild to moderate skin rashes, transient and clinically 
insignificant hyperbilirubinemia and myelosuppression. 
Grade 3/4 neutropenia occurred in 9% of patients who got 
nilotinib at the 400 mg twice daily dose and in 22% of patients 
that received the 600 mg twice a day dose (Table 4).
In the larger phase II trial of nilotinib in IM-resistant/
intolerant CP-CML, 280 patients were evaluable for safety 
and tolerability.33 The most frequent grade 3 or 4 hematologic 
toxicities reported in this study were neutropenia (29%) and 
thrombocytopenia (29% also); the median duration for both 
events was 15 and 22 days respectively.
Dose interruptions were required in 10% and 19% of 
patients and platelet transfusions or growth factor support 
was required in 10% and 5% of patients respectively. Of 
the non-hematologic toxicities observed, the most common 
were rash, nausea, pruritus, headache and fatigue. Grade 
3 or 4 elevation in AST or ALT levels were infrequent 
(1% and 4% of patients respectively), grade 3/4 hyper-
bilirubinemia occurred in 9% of cases (likely related to 
the UGT1A1 polymorphism discussed previously), 14% 
of patients had elevated lipase levels and pancreatitis was 
seen in 1% of patients. Prolongation of the QT interval (by 
over 500 msec) from baseline was seen in 1% of cases. 
Preclinical signal in assays of potential to prolong QTc 
has given very similar data on nilotinib and dasatinib. 
Nilotinib has been studied in normal volunteers and has no 
pro-arrythmogenic potential – this study has not yet been 
performed with dasatinib. Fluid retention events (weight 
gain, edema, pleural and pericardial effusions) occurring 
in trials with IM36 and dasatinib were not commonly seen 
in patients treated with nilotinib. Only 3 grade1/2 events 
occurred in the phase II CML-CP study33 and none were 
reported in the phase II CML-AP trial (Table 6). The tox-
icity data for blastic phase CML in patients treated with 
dasatinib as second-line therapy are presented in Table 5 
for comparison.37
In the second published phase II trial of nilotinib in 
patients with IM-resistant or -intolerant AP reported on by 
le Coutre et al,34 119 patients were enrolled and all were 
evaluable for safety and tolerability. Similar to the CML-CP Drug Design, Development and Therapy 2009:3 95
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study33 rash (22% of cases), pruritus (20%), constipation 
(11%), headache (10%), fatigue (10%) and nausea (10%) 
were the most frequent non-hematologic events. Grade 3 
or 4 adverse events were uncommon. The most common 
grade 3/4 hematologic toxicities were anemia, neutropenia 
and thrombocytopenia in 13%, 21% and 35% of patients 
respectively. No clinically signiﬁ  cant electrocardiographic 
changes were observed in this trial. Safety and tolerability 
data from the other phase II trial of CML-BP patients is 
broadly comparable to the chronic and accelerated phase II 
studies.
Data from the ENACT study (Expanding Nilotinib 
Access in Clinical Trials) was presented at the European 
Hematology Association (EHA) in June 2008.38 This ongoing 
open label, multicenter trial was initiated to provide expanded 
access to nilotinib and to obtain additional safety information 
15%
45%
55%
8%
7%
3% 5%
T3151
F359C/V
E255K/V
Y253H
IC50 ≤ 150 nM or unknown IC50 to nilotinib
IC50 ≤ 150 nM to nilotinib
No Mutation
No mutation
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(T3151, Y253H, E255K/V, F359C/V)
Nilotinib Phase II
Treated Resistant Resistant
with any mutation
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
IRIS 5-year Follow-up
Responding patients
Resistant patients
Unknown IC60
IC60 ≤ 150 nM
Figure 3 Distribution of mutated phenotypes in imatinib-resistant or -intolerant CML.
Table 3 Most published reports use the same deﬁ  nitions of hematologic and cytogenetic responses, with minor variations (the deﬁ  nitions 
proposed by ELN are summarized here)
Deﬁ  nition Monitoring
Hematologic response (complete) Platelet count 450 × 109/L WBC 
count 10 × 109/L. Differential: without 
immature granulocytes and with 5% 
basophils. Non-palpable spleen
Check every 2 weeks until complete response 
achieved and conﬁ  rmed, then every 3 months 
unless otherwise speciﬁ  ed
Cytogenetic response Complete: Ph+ none. Partial: 
Ph+ 1%–35%. Minor: Ph+ 36%–65%. 
Minimal: Ph+ 66%–95%. None: Ph+  95%
Check every 6 months until complete response 
achieved and conﬁ  rmed
Molecular response (BCR-ABL: 
control gene ratio according to 
an international scale)
Complete: transcript non-detectable 
Major: 0.1%
Check every 3 months; mutational analysis 
only in case of failure, suboptimal response 
or increased level of transcript
Abbrevation: WBC, white blod cells.Drug Design, Development and Therapy 2009:3 96
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in patients with all phase CML with prior IM resistance/
intolerance. Patients received nilotinib at the 400 mg twice 
daily dose. Dose escalation was not permitted. Patients that 
required a dose reduction to 400 mg once a day were allowed 
to have their doses escalated to twice daily after resolution 
of toxicity, lack of response or persistent disease at the 
discretion of the investigator. More than 1600 patients have 
been enrolled and results were available for 1056 patients 
(CP, n = 818, AP, n = 120, BP, n = 118). The main toxicities 
reported for nilotinib therapy were similar to those in the 
phaseI/II studies discussed above. The majority of adverse 
events were hematologic, with the most common grade 3/4 
toxicities being thrombocytopenia (22%) and neutropenia 
(13%). Non-hematologic toxicities were mostly mild and 
included headache, rash and nausea. Death occurred in 28 
(3%) of patients and was more common in those with BP 
disease (n = 15). An average sudden death rate of 0.6% annu-
ally has been observed among patients on the nilotinib studies 
which is directly comparable to that seen on other studies 
in patients with CML receiving IM or dasatinib therapy. 
Across the large phase II trials of nilotinib, the median doses 
received were very close to the planned treatment doses of 
800 mg daily (Figure 4).
Cross intolerance between IM and nilotinib is negligible, 
reﬂ  ecting the more effective targeting of Bcr-Abl by the latter 
agent and thus nilotinib is the agent of choice in patients with 
all forms of IM intolerance (Figure 2).39
Efﬁ  cacy data
Efﬁ  cacy data are available from the phase I trial32 and the 
three phase II studies33–35 conducted in patients with CP, AP 
and BP CML as well as a nilotinib third-line phase II trial 
in patients with both IM and dasatinib failure.
Phase 1 trial
In patients with CML-CP,32 11 of 17 patients (65%) 
achieved a CHR. A major cytogenetic remission occurred 
in 6 patients (35%) and 9 patients (53%) got at least some 
form of cytogenetic remission (minimal, major or minor). 
In the patients with CML-AP (n = 56), 26 (46%) got a 
CHR and 15 (27%) achieved a MCyR, 38 patients (74%) 
got hematologic remissions (complete response, marrow 
response, or return to chronic phase disease) and 31 (55%) 
achieved cytogenetic remissions. Of the 33 patients with 
CML-BP, 2 (6%) had a CHR and 6 (18%) had a MCyR 
with nilotinib. Thirteen patients (39%) got some form of 
hematologic response and 9 patients (27%) achieved a 
cytogenetic response (minimal, major or minor). Patients who 
failed to respond to initial therapy with nilotinib responded 
with increased dosing. Of the 23 patients with AP or BP 
Table 4 Toxicity data from the phase I safety tolerability trial
Adverse event Toxicity grade (n = 119)
Grade 1 or 2 (%) Grade 3 or 4 (%)
Non-hematological event
  Rash (all types) 20 2
 Pruritus 15 2
 Dry  skin 12 0
 Constipation 8 0
  Nausea, vomiting or both 8 0
  Increase in both total and conjugated bilirubin levels 5 3
 Fatigue 5 1
  Increase in unconjugated bilirubin level 2 4
 Alopecia 6 0
  Increase in lipase level 0 5
  Increase in level of ALT,   AST, or both 1 3
Hematological event
 Thrombocytopenia 1 20
 Neutropenia 1 13
 Anemia 3 6
Notes: Grade 3 or 4 events were primarily hematological as expected. Most adverse events were mild and non-hematological. Grade 3/4 hyperbillirubinemia was rare and 
primarily indirect and related to polymorphisms in the UCT1A1 gene.   The toxicity proﬁ  les of the subsequent all phase CML studies were comparable to the phase I study.Drug Design, Development and Therapy 2009:3 97
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disease who had a dose escalation from 50 to 400 mg once 
daily to 400 mg or 600 mg twice daily, 13 (57%) of those 
had hematologic responses. Nilotinib was equally effective 
in those with and without ABL kinase mutations in those that 
had mutational analysis carried out (n = 91).
Phase II trial in chronic phase CML
In this study, 280 CML-CP phase patients were evaluated.33 
The primary end-point of the trial was major cytogenetic 
response. The median duration of CML was 57 months. 
Patients were enrolled with either IM-refractory (69%) or 
-intolerant disease (31%) and the majority had received 
prior therapy with interferon (66%), hydoxyurea (83%) 
and/or cytarabine (25%). Responses were comparable in 
both the IM-resistant or -intolerant groups. Major cytogenetic 
responses were observed in 48% of patients and CCyRs 
were seen in 31% of cases. The median time to MCyR was 
2.8 months giving a projected survival at 1 year of 95%. 
Just 5 patients (4%) who got a MCyR stopped therapy due 
to death or disease progression. Complete hematologic 
Table 5 Toxicity data for dasatinib phase II study in patients with blastic phase CML37
Adverse event Patients N (%)
MBP-CML (n = 109) LBP-CML (n = 48)
All grades Grade 3/4 All grades Grade 3/4
Non-hematologic events
  Diarrhea 43 (39) 8 (7) 16 (33) 1 (2)
  Pleural effusion 39 (36) 16 (15) 6 (13) 3 (6)
  Vomiting 24 (22) 3 (3) 12 (25) 1 (2)
  Dyspnea 23 (21) 7 (6) 6 (13) 1 (2)
  Pyrexia 22 (20) 5 (5) 8 (17) 1 (2)
  Nausea 21 (19) 4 (4) 12 (25) 0
  Fatigue 20 (18) 2 (2) 13 (27) 2 (4)
  Peripheral edema 20 (18) 0 6 (13) 0
  Rash 15 (14) 0 8 (17) 2 (4)
  Febrile neutropenia 5 (5) 5 (5) 8 (17) 7 (15)
  Asthenia 13 (12) 2 (2) 4 (8) 1 (2)
  Anorexia 12 (11) 1 (1) 3 (6) 0
  GI hemorrhage 11 (10) 6 (6) 0 0
  Headache 11 (10) 2 (2) 8 (17) 1 (2)
  Epistaxis 11 (10) 2 (2) 1 (2) 0
  Cough 11 (10) 1 (1) 3 (6) 0
Hematological events
  Leukocytopenia 67 (61) 34 (71)
  Neutropenia 87 (80) 39 (81)
  Thrombocytopenia 89 (82) 42 (88)
  Anemia 75 (69) 24 (50)
Abbreviations: MBP, myeloid blast phase; LBP, lymphoid blast phase.
Table 6 Fluid retention events for nilotinib in IM refractory/intolerant CML patients in accelerated phase (AP) and blastic phase (BP) 
disease
AP (N = 138) BP (N = 136)
All Grades n (%) Grades 3 or 4 n (%) All Grades n (%) Grades 3 or 4 n (%)
Peripheral edema 6 (4.4) 0 12 (9) 1 (1)
Pericardial effusion 0 0 0 (0) 0 (0)
Pleural effusion 0 0 (1) 0 (0)
Pulmonary edema 1 (0.7) 1 (0.7) 0 (0) 0 (0)Drug Design, Development and Therapy 2009:3 98
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responses were seen in 137 of 185 patients who had active 
disease at enrollment (74%) and the median time to response 
in this group was 1 month. Of the patients with ABL kinase 
mutations, 42% had a MCyR, compared to 51% of those 
without mutations. Results for CCyRs were respectively 23% 
and 35%. Major cytogenetic responses were observed across 
all BCR-ABL genotypes except in the 4 patients (2.2%) that 
harbored a T315I mutation.
Phase II trial in accelerated phase CML
In the trial by le Coutre et al34 119 patients with IM-resistant 
(81%) or -intolerant (19%) accelerated phase CML were 
enrolled. The primary endpoint in this study was hema-
tologic response. Cytogenetic response was an important 
secondary endpoint. Patients had received a diagnosis of 
CML for a median duration of 71 months and were on IM 
therapy for a median of 32 months prior to enrollment. 
Similar to the phase II CML-CP study, most patients had 
received treatment with either hydroxyurea, interferon or 
cytarabine in addition to IM. Patients were treated with 
400 mg of nilotinib twice daily; this dose could be increased 
to 600 mg twice daily as required. The overall hematologic 
response rate was 47% with a median time to response of 
I month. Twenty-six percent of patients achieved a CHR. 
In the patients who achieved cytogenetic responses, 29% 
got a MCyR and 16% got a CCyR. The median time to 
major cytogenetic response was 2 months, the median 
duration of response lasting 15.4 months. At 12 months, 
the estimated overall survival was 79% of the 119 patients 
evaluated. Results of this trial (n = 136) were updated at 
EHA in June 2008.
Phase II trial in blastic phase CML
Efﬁ  cacy data for 136 CML-BP patients was presented 
recently at EHA.35 Of these 82% were IM resistant and 
18% were IM intolerant. The primary endpoint for this 
trial was conﬁ  rmed hematologic response. The majority of 
patients had received prior therapies (34% had interferon, 
37% had cytarabine and 13% had been transplanted). At 
the time of enrollment, 38% of patients had over 95% 
Ph+ metaphases, with additional chromosomal abnormali-
ties in 53% of patients. Conﬁ  rmed hematologic response 
was seen in 29 patients (21%), and 15 patients (11%) 
got a CHR. Major cytogenetic remission was achieved 
in 55 patients (40%), and 40 patients (29%) got CCyRs. 
Overall survival at 12 months was 42%. Patients with 
myeloid and lymphoid blast crisis had similar survival 
outcomes.
Phase II trials of nilotinib as third-line 
therapy
Data are available for 42 patients with all-phase CML who 
failed both IM and dasatinib.40,41 Of these, 16 had chronic 
phase disease, 9 had accelerated phase disease and 17 were 
in blast crisis. All patients got nilotinib in the standard 
doses (400 mg BID which could be increased to 600 mg 
BID if necessary). Median age was 58 (19–78 years) years 
and the median time elapsed since first diagnosed was 
81 (4–420) days. The primary endpoint for CP patients was 
CyR and the primary endpoint for AP patients was HR. 
Of the 16 evaluable CP-CML patients, 13 had no baseline 
CHR. Four of 13 patients (31%) had a MCyR, 2 complete 
(15%) and 2 partial (15%). Five of 13 patients (38%) got a 
(CP)
n = 316
Delivered
(AP)
n = 138
800 
Delivered
(BP)
n = 136 
Delivered Planned
775  800 797
Figure 4 Nilotinib phase II dosing.   The planned nilotinib phase II dose was 800 mg per day. The median doses for the chronic phase (CP), accelerated phase (AP) and blastic 
phase (BP) studies are shown and indicate that nilotinib was well tolerated in all three groups.Drug Design, Development and Therapy 2009:3 99
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CHR. Of the 9 AP patients, 2 (22%) returned to CP, 6 (67%) 
were not evaluable and there was 1 death (11%). Of the 17 
CML-BP patients 3 (18%) had a CHR, I returned to CP (6%), 
5 had stable disease (29%), 4 (24%) were not evaluable and 
4 (24%) had progressive disease (Table 7 and Figure 5).
Conclusions and future directions
Nilotinib has proven to be optimal second line therapy in 
CML based on 1) its efﬁ  cacy in all disease phases; 2) its 
minimal cross intolerance with IM; 3) its activity across 
the entire spectrum of BCR-ABL mutations except T315I; 
4) its low incidence of grade 3/4 extramedullary AEs 
(adverse events) which tend to occur early in therapy; 5) its 
relatively low incidence of severe myelosuppressive AEs; 
and 6) its considerably superior tolerability over long periods 
at full prescribed approved doses relative to dasatinib. 
Phase III studies are underway in patients with newly diag-
nosed CML, where the goal of treatment will be to prevent 
the emergence of resistant clones and improve survival over 
the current standard, IM. Nilotinib has been approved by the 
FDA for the treatment of adults with CP or AP CML who 
are either resistant or intolerant of prior therapies including 
IM. Nilotinib has also been licensed for these indications by 
the EMEA in Europe and numerous other regulatory agen-
cies. The rapid transition of nilotinib through the regulatory 
process represents a true triumph of rational anti-cancer 
agent design and builds on the expectations of the enormous 
success of IM in the clinic.
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Figure 5 Overall survival for nilotinib as third-line therapy for patients resistant or intolerant of both imantinib and dasatinib.
Abbreviations: CP, chronic phase;   AP, accelerated phase; BP, blastic phase.
Table 7 Phase I/II response rates for nilotinib in three second-line phase II trials and one third-line phase II trial (soon to be published)
Response Phase 1 study 
(n = 119)
Phase II second-line studies Phase II third-line study
Chronic phase 
(n = 280)
Accelerated 
phase (n = 119)
Blastic phase 
(n = 136)
Chronic phase 
(n = 16)
Accelerated 
phase (n = AP)
Blastic phase 
(n = 17)
Hematological 
responses (total)
58% NA 47% 21% NA 22% NA
CHR 37% 74% 26% 15% 38% NA 18%
Cytogenetic 
responses (total)
55% 70% 66% NA NA NA NA
MCyR 25% 48% 29% 40% 31% NA NA
CCyR 15% 31% 16% 29% 15% NA NA
Abbreviations: CHR, complete hematologic response, MCyR, major cytogenetic response, CCyR, complete cytogenetic response, NA, not available.Drug Design, Development and Therapy 2009:3 100
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